Advancements in Treating Moderate-to-Severe Plaque Psoriasis

27 November 2023

By UCB

Bimekizumab provides a rapid and long-term response in patients with moderate-to-severe plaque psoriasis. At the (EADV) 2023 Congress, three posters were presented reporting 3-year results from the Phase III/IIIb clinical trials of Bimekizumab.

Click here to read the results!

Related content

Shape External link

Tip sheet on how to manage psoriatic disease when planning to have a family from parents to future parents.

Shape External link

Article from EUROPSO raises important points to remember when women are planning to have children.

Combined Shape
Screenshot 2024 12 10 152634

Article Stigma, Care and Treatment

Recommendations for Health Care Professionals
Combined Shape
Combined Shape

webinar Stigma, Living with Psoriatic Disease, Care and Treatment, IFPA Webinar Series

IFPA Webinar - The Path to Pleasure: Shedding the Stigma of Psoriatic Disease and Intimacy

Shape External link

The Impact of Psoriatic Disease on a Woman’s Career, Family Planning, Social Life and Mental: results from a 2021 survey on women living in Europe.